Moody's Corp. provides credit ratings, research, tools and analysis to the global capital markets. The company operates through the following segments: Moody's Investors Service and Moody's Analytics. The Moody's Investors Service segment is a credit rating agency, which publishes credit ratings on debt obligations and the entities, including various corporate and governmental obligations, structured finance securities and commercial paper programs. This segment consists of four lines of business, including corporate finance, structured finance, financial institutions and public, project and infrastructure finance. The Moody's Analytics segment develops products and services, which support financial analysis and risk management activities of institutional participants in global financial markets. This segment operates through three lines of business: Research, Data and Analytics, Enterprise Risk and Professional Services. The Research, Data and Analytics business distributes research and data developed by MIS as part of its ratings process, including in-depth research on major debt issuers, industry studies and commentary on topical credit related events and also provides economic research and credit data and analytical tools such as quantitative credit risk scores. The Enterprise Risk business provides software solutions and related risk management services. The Professional Services business provides outsourced research and analytical services along with financial training and certification programs. The company was founded in 1900 by John Moody and is headquartered in New York, NY.
Once regarded as boring and fundamentally defensive, global healthcare stocks have re-emerged over the last few years as a powerhouse for future growth. Even though the S&P 500's healthcare sector is up over 20 per cent in the past year, it continues to offer more compelling entry points than its ASX-listed counterparts.
Given the strong run experienced by healthcare stocks globally, there are few – if any – absolute bargains left to pick off. Nevertheless, when you factor in their potential future upside, they still offer more compelling valuation propositions than their Aussie healthcare stocks. We found 9 future top performers in Skaffold Global.